Terms: = Leukemia AND JAK1, ENSG00000162434, P23458, JTK3, JAK1B, JAK1A, 3716 AND Prognosis
41 results:
1. Regulatory function and mechanism research for m6A modification WTAP via SUCLG2-AS1- miR-17-5p-jak1 axis in AML.
Liu M; Yu B; Tian Y; Li F
BMC Cancer; 2024 Jan; 24(1):98. PubMed ID: 38233760
[TBL] [Abstract] [Full Text] [Related]
2. Whole-genome CRISPR screening identifies molecular mechanisms of PD-L1 expression in adult T-cell leukemia/lymphoma.
Chiba M; Shimono J; Suto K; Ishio T; Endo T; Goto H; Hasegawa H; Maeda M; Teshima T; Yang Y; Nakagawa M
Blood; 2024 Apr; 143(14):1379-1390. PubMed ID: 38142436
[TBL] [Abstract] [Full Text] [Related]
3. Proof of concept of triple COMBI therapy to prohibit MPN progression to AML.
Hasselbalch HC; Skov V; Kjaer L; Larsen MK
Br J Haematol; 2024 Jan; 204(1):16-18. PubMed ID: 37957927
[TBL] [Abstract] [Full Text] [Related]
4. CALCRL induces resistance to daunorubicin in acute myeloid leukemia cells through upregulation of XRCC5/TYK2/jak1 pathway.
Tang S; Li S; Shi X; Sheng L; Mu Q; Wang Y; Zhu H; Xu K; Zhou M; Xu Z; Wu A; Ouyang G
Anticancer Drugs; 2024 Feb; 35(2):163-176. PubMed ID: 37948318
[TBL] [Abstract] [Full Text] [Related]
5. XBP1 promotes NRAS
Salimi A; Schemionek-Reinders M; Huber M; Vieri M; Patterson JB; Alten J; Brümmendorf TH; Kharabi Masouleh B; Appelmann I
J Cell Mol Med; 2023 Nov; 27(21):3363-3377. PubMed ID: 37753803
[TBL] [Abstract] [Full Text] [Related]
6. The JAK3
Lahera A; Vela-Martín L; Fernández-Navarro P; Llamas P; López-Lorenzo JL; Cornago J; Santos J; Fernández-Piqueras J; Villa-Morales M
Mol Carcinog; 2024 Jan; 63(1):5-10. PubMed ID: 37712558
[TBL] [Abstract] [Full Text] [Related]
7. Characteristics of Molecular Genetic Mutations and Their Correlation with prognosis in Adolescent and Adult Patients with Acute Lymphoblastic leukemia.
Sun X; Liu X; Li Y; Shi X; Li Y; Tan R; Jiang Y; Sui X; Ge X; Xu H; Wang X; Fang X
Oncology; 2024; 102(1):85-98. PubMed ID: 37437551
[TBL] [Abstract] [Full Text] [Related]
8. Interferon gamma regulates a complex pro-survival signal network in chronic lymphocytic leukemia.
Chen Y; Shao X; Yang H; Ren L; Cui Y; Zhang W; Macip S; Meng X
Eur J Haematol; 2023 Apr; 110(4):435-443. PubMed ID: 36576398
[TBL] [Abstract] [Full Text] [Related]
9. The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes.
Moyo TK; Mendler JH; Itzykson R; Kishtagari A; Solary E; Seegmiller AC; Gerds AT; Ayers GD; Dezern AE; Nazha A; Valent P; van de Loosdrecht AA; Onida F; Pleyer L; Cirici BX; Tibes R; Geissler K; Komrokji RS; Zhang J; Germing U; Steensma DP; Wiseman DH; Pfeilstöecker M; Elena C; Cross NCP; Kiladjian JJ; Luebbert M; Mesa RA; Montalban-Bravo G; Sanz GF; Platzbecker U; Patnaik MM; Padron E; Santini V; Fenaux P; Savona MR;
BMC Cancer; 2022 Sep; 22(1):1013. PubMed ID: 36153475
[TBL] [Abstract] [Full Text] [Related]
10. Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis.
Palandri F; Bartoletti D; Iurlo A; Bonifacio M; Abruzzese E; Caocci G; Elli EM; Auteri G; Tiribelli M; Polverelli N; Miglino M; Heidel FH; Tieghi A; Benevolo G; Beggiato E; Fava C; Cavazzini F; Pugliese N; Binotto G; Bosi C; Martino B; Crugnola M; Ottaviani E; Micucci G; Trawinska MM; Cuneo A; Bocchia M; Krampera M; Pane F; Lemoli RM; Cilloni D; Vianelli N; Cavo M; Palumbo GA; Breccia M
Cancer; 2022 Jul; 128(13):2449-2454. PubMed ID: 35363892
[TBL] [Abstract] [Full Text] [Related]
11. Recent Advances in the Use of Molecular Analyses to Inform the Diagnosis and prognosis of Patients with Polycythaemia Vera.
Stuckey R; Gómez-Casares MT
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34068690
[TBL] [Abstract] [Full Text] [Related]
12. Double and single mixed-lineage leukemia-rearranged subclones in pediatric acute myeloid leukemia: a case report.
McGrath M; Smink G
J Med Case Rep; 2021 May; 15(1):228. PubMed ID: 33957966
[TBL] [Abstract] [Full Text] [Related]
13. A JAK/STAT-mediated inflammatory signaling cascade drives oncogenesis in AF10-rearranged AML.
Chen BR; Deshpande A; Barbosa K; Kleppe M; Lei X; Yeddula N; Vela PS; Campos AR; Wechsler-Reya RJ; Bagchi A; Meshinchi S; Eaves C; Jeremias I; Haferlach T; Frank DA; Ronai Z; Chanda S; Armstrong SA; Adams PD; Levine RL; Deshpande AJ
Blood; 2021 Jun; 137(24):3403-3415. PubMed ID: 33690798
[TBL] [Abstract] [Full Text] [Related]
14. The delta isoform of phosphatidylinositol-3-kinase predominates in chronic myelomonocytic leukemia and can be targeted effectively with umbralisib and ruxolitinib.
Villaume MT; Arrate MP; Ramsey HE; Sunthankar KI; Jenkins MT; Moyo TK; Smith BN; Fischer MA; Childress MA; Gorska AE; Ferrell PB; Savona MR
Exp Hematol; 2021 May; 97():57-65.e5. PubMed ID: 33617893
[TBL] [Abstract] [Full Text] [Related]
15. [Clinical Analysis of Gene Mutation in Adult Patients with B-ALL and Its Influence on Clinical prognosis].
Deng M; Zuo WL; Zhang CL; Wei XD; Li XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Dec; 28(6):1867-1872. PubMed ID: 33283712
[TBL] [Abstract] [Full Text] [Related]
16. [Gene Mutation in Acute Lymphoblastic leukemia by DNA Sequencing].
Zheng RY; Wang SJ; Wang C; Li T; Liao LX; Li ML; Chen SM; Guo R; Wang WQ; Zhang Y; Fan Y; Wan DM; Liu YF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Dec; 28(6):1791-1795. PubMed ID: 33283700
[TBL] [Abstract] [Full Text] [Related]
17. Failure of tofacitinib to achieve an objective response in a
Wong J; Wall M; Corboy GP; Taubenheim N; Gregory GP; Opat S; Shortt J
Cold Spring Harb Mol Case Stud; 2020 Aug; 6(4):. PubMed ID: 32843425
[TBL] [Abstract] [Full Text] [Related]
18. Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era.
Masarova L; Bose P; Pemmaraju N; Daver NG; Zhou L; Pierce S; Sasaki K; Kantarjian HM; Estrov Z; Verstovsek S
Cancer; 2020 Oct; 126(19):4322-4331. PubMed ID: 32697338
[TBL] [Abstract] [Full Text] [Related]
19. Adult T-cell acute lymphoblastic leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem-cell transplantation.
Kim R; Boissel N; Touzart A; Leguay T; Thonier F; Thomas X; Raffoux E; Huguet F; Villarese P; Fourrage C; Passini L; Hunault M; Lepretre S; Chevallier P; Braun T; Lhéritier V; Chantepie S; Maury S; Escoffre M; Tavernier E; Chalandon Y; Graux C; Macintyre E; Ifrah N; Asnafi V; Dombret H; Lhermitte L;
Leukemia; 2020 Jul; 34(7):1730-1740. PubMed ID: 31992840
[TBL] [Abstract] [Full Text] [Related]
20. The use of PanDrugs to prioritize anticancer drug treatments in a case of T-ALL based on individual genomic data.
Fernández-Navarro P; López-Nieva P; Piñeiro-Yañez E; Carreño-Tarragona G; Martinez-López J; Sánchez Pérez R; Aroca Á; Al-Shahrour F; Cobos-Fernández MÁ; Fernández-Piqueras J
BMC Cancer; 2019 Oct; 19(1):1005. PubMed ID: 31655559
[TBL] [Abstract] [Full Text] [Related]
[Next]
